First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis

BACKGROUND: The aim of the present study was to evaluate the cost-effectiveness of durvalumab plus platinum–etoposide versus platinum–etoposide as first-line treatments for small-cell lung cancer from the perspective of the US payer. METHODS: This study established a partition survival model for thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Longfeng, Hang, Yongfu, Liu, Maobai, Li, Na, Cai, Hongfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747765/
https://www.ncbi.nlm.nih.gov/pubmed/33344252
http://dx.doi.org/10.3389/fonc.2020.602185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747765/
https://www.ncbi.nlm.nih.gov/pubmed/33344252
http://dx.doi.org/10.3389/fonc.2020.602185

Ejemplares similares